| Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ... Studies in health technology and informatics 216, 574, 2015 | 1124 | 2015 |
| Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery GN Norén, J Hopstadius, A Bate Statistical methods in medical research 22 (1), 57-69, 2013 | 239 | 2013 |
| Temporal pattern discovery in longitudinal electronic patient records GN Norén, J Hopstadius, A Bate, K Star, IR Edwards Data Mining and Knowledge Discovery 20, 361-387, 2010 | 207 | 2010 |
| Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events GN Norén, A Bate, R Orre, IR Edwards Statistics in medicine 25 (21), 3740-3757, 2006 | 190 | 2006 |
| A statistical methodology for drug–drug interaction surveillance GN Norén, R Sundberg, A Bate, IR Edwards Statistics in medicine 27 (16), 3057-3070, 2008 | 181 | 2008 |
| vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues T Bergvall, GN Norén, M Lindquist Drug safety 37, 65-77, 2014 | 178 | 2014 |
| Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase K Star, GN Norén, K Nordin, IR Edwards Drug safety 34, 415-428, 2011 | 161 | 2011 |
| Duplicate detection in adverse drug reaction surveillance GN Norén, R Orre, A Bate, IR Edwards Data Mining and Knowledge Discovery 14, 305-328, 2007 | 138 | 2007 |
| Good signal detection practices: evidence from IMI PROTECT AFZ Wisniewski, A Bate, C Bousquet, A Brueckner, G Candore, K Juhlin, ... Drug safety 39, 469-490, 2016 | 137 | 2016 |
| Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase® RE Chandler, K Juhlin, J Fransson, O Caster, IR Edwards, GN Norén Drug safety 40, 81-90, 2017 | 111 | 2017 |
| Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank: retrospective evaluation against emerging safety signals O Caster, K Juhlin, S Watson, GN Norén Drug safety 37, 617-628, 2014 | 100 | 2014 |
| Large‐scale regression‐based pattern discovery: the example of screening the WHO global drug safety database O Caster, GN Norén, D Madigan, A Bate Statistical Analysis and Data Mining: The ASA Data Science Journal 3 (4 …, 2010 | 92 | 2010 |
| Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second‐generation antipsychotics J de Leon, EJ Sanz, GN Norén, C De las Cuevas World Psychiatry 19 (1), 120, 2020 | 81 | 2020 |
| Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR J van Stekelenborg, J Ellenius, S Maskell, T Bergvall, O Caster, ... Drug Safety 42, 1393-1407, 2019 | 74 | 2019 |
| Impact of stratification on adverse drug reaction surveillance J Hopstadius, GN Norén, A Bate, IR Edwards Drug safety 31, 1035-1048, 2008 | 69 | 2008 |
| Temporal pattern discovery for trends and transient effects: its application to patient records GN Norén, A Bate, J Hopstadius, K Star, IR Edwards Proceedings of the 14th ACM SIGKDD international conference on Knowledge …, 2008 | 69 | 2008 |
| Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest RD Boyce, PB Ryan, GN Norén, MJ Schuemie, C Reich, J Duke, ... Drug safety 37, 557-567, 2014 | 62 | 2014 |
| Assessment of the utility of social media for broad-ranging statistical signal detection in pharmacovigilance: results from the WEB-RADR project O Caster, J Dietrich, ML Kürzinger, M Lerch, S Maskell, GN Norén, ... Drug safety 41, 1355-1369, 2018 | 57 | 2018 |
| Modern methods of pharmacovigilance: detecting adverse effects of drugs GN Norén, IR Edwards Clinical medicine 9 (5), 486, 2009 | 56 | 2009 |
| Performance of stratified and subgrouped disproportionality analyses in spontaneous databases S Seabroke, G Candore, K Juhlin, N Quarcoo, A Wisniewski, R Arani, ... Drug safety 39, 355-364, 2016 | 53 | 2016 |
Andrew BateGSK, LSHTMVerified email at gsk.com
